Get to know our clinical trials

Placebo-controlled, parallel-group clinical trial to verify the benefit of aducanumab in participants with Alzheimer's disease.

THE GOAL OF THE TRIAL IS TO SEE IF ADUCANUMAB (ADUHELMTM, ALSO KNOWN AS BIIB037, THE TRIAL DRUG) CAN HELP SLOW THE DEVELOPMENT OF AD (ALZHEIMER'S DISEASE) SYMPTOMS IN PEOPLE WITH EARLY AD.

Imagen Dr. Mario Riverol Fernandez, Departamento de Neurologia.
Dr. Mario Riverol Fernández Curriculum
Specialist Neurology Department
Navarre headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE IIIB/IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO VERIFY THE CLINICAL BENEFIT OF ADUCANUMAB (BIIB037) IN PARTICIPANTS WITH ALZHEIMER'S DISEASE.
  • Code EudraCT: .
  • Protocol number: 221AD305
  • Promoter: Biogen
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION